OncoCyte Corp Stock News

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year

OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Pa

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call P

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results o

Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).

IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earning

The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.

Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products t

The Dow Jones settled slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around t

Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its

OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0